Fig. 3.

Change in monthly headache frequency during combination therapy with onabotulinumtoxinA and a CGRP monoclonal antibody. a Mean change from baseline and b percentage of patients with a ≥ 50% reduction from baseline in monthly headache frequency in the primary analysis cohort. c Mean change from baseline and d percentage of patients with a ≥ 50% reduction from baseline in monthly headache frequency in the AHS CGRP mAb cohort. AHS American Headache Society, CGRP calcitonin gene–related peptide, CI confidence interval, mAb monoclonal antibody